New drug cocktail aims to tame tough pancreatic cancer
NCT ID NCT05273554
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether combining two drugs, pembrolizumab (Keytruda) and lenvatinib, can help control advanced pancreatic cancer that has already been treated. Fifteen participants will receive the combination to see if it shrinks tumors. The goal is to gather initial data on effectiveness and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and lenvatinib
What this could lead to
If it works, this could point toward a new treatment option for advanced pancreatic cancer that has not responded to prior therapy.
What could go wrong
This is a very early, small pilot study with only 15 participants. The combination may not shrink tumors or improve survival, and side effects from the drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States